In various embodiments nanoparticle drug delivery vehicles are provided that specifically deliver a cargo to a target pathogenic organism. In certain embodiments the drug delivery vehicle comprises a mesoporous silica nanoparticle comprising a plurality of pores and an outer surface through which the pores are disposed; a cargo disposed in the pores; one or more antigens attached to the surface of the nanoparticle; an antibody that specifically binds the antigens and are bound to the antigens, wherein the antibody inhibits diffusion of the cargo out of the pores and permit release of the cargo when the drug delivery vehicle is in the presence of the antigen or a pathogen displaying the antigen.

The present disclosure is directed to antibodies binding to and neutralizing the coronavirus designated SARS-CoV-2 and methods for use thereof.

Subject matter of the present invention is a method for (a) diagnosing or predicting the risk of life-threatening deterioration or an adverse event or (b) prognosing the severity or (c) predicting or monitoring the success of a therapy or intervention in a patient infected with a Corona virus, the method comprising: determining the level of pro-Adrenomedullin (SEQ ID No. 31) or fragment thereof in a sample of bodily fluid of said patient, comparing said level of pro-Adrenomedullin or fragment thereof to a pre-determined threshold or a previous level of pro-Adrenomedullin or fragment thereof, and correlating said level of pro-Adrenomedullin or fragment thereof with the risk of life-threatening deterioration or an adverse event, or correlating said level of pro-Adrenomedullin or fragment thereof with the severity, or correlating said level of pro-Adrenomedullin or fragment thereof with the success of a therapy or intervention,
wherein said pro-Adrenomedullin or fragment thereof is selected from the group consisting of PAMP (SEQ ID No. 32), MR-proADM (SEQ ID No. 33), ADM-NH2 (SEQ ID No. 20), ADM-Gly (SEQ ID No. 21) and CT-proADM (SEQ ID No. 34).

Subject matter of the present invention is an Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold for use in therapy or intervention in a patient in a patient infected with a Corona virus.

Provided are antibodies or antigen binding portions thereof that specifically bind Dengue virus, various compositions of such antibodies or antigen binding portions thereof, and methods of their use. The disclosure provides such antibodies, fragments of such antibodies retaining Dengue virus-binding ability, pharmaceutical compositions including such antibodies or antigen binding fragments thereof, and diagnostic compositions including such antibodies or antigen binding fragments thereof. This disclosure further provides for isolated nucleic acids encoding such antibodies, amino acid sequences of such antibodies, and host cells transformed therewith. Additionally, this disclosure provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the disclosure.

In embodiments there is described a method for reducing false positives and negatives in the detection of SARS-CoV-2 in suspected patients using mass spectroscopy employing the steps of mixing samples of collected saliva and nasopharyngeal secretions in a single sample container; adding universal transport medium to the mixed samples in said single sample container; transporting the single sample container at a temperature above 0° C. to a remote location; deactivation of viral content of the mixed sample; protein digestion of the mixed sample; concomitant separation of peptides, ionization by mass spectroscopy of the separated peptides, and comparison of peptide patterns to known SARS-CoV-2 peptides. Also set forth in an embodiment is a collection container for collecting saliva and/or sputum, as well as a swab member, with universal transport medium and/or virus inactivating agent housed in separate compartment communicable with sample compartment through a one-way valve.

The present specification describes methods and systems for treating a patient having a SARS-CoV-2 virus load greater than a predefined threshold. A patient is assessed to determine if the patient has the SARS-CoV-2 virus load greater than the predefined threshold. If the patient has the SARS-CoV-2 virus load greater than the predefined threshold, a volume of plasma is removed from the patient. In a plasma delipidation system, the volume of plasma is mixed with an extraction solvent to delipidate at least some of the SARS-CoV-2 viruses in the patient's SARS-CoV-2 virus load, thereby causing one or more modifications to the SARS-CoV-2 viruses. The extraction solvent is removed from the plasma and the plasma is administered with the at least some of the delipidated SARS-CoV-2 viruses to the patient.

A kit, composition and method for detection of antibodies to severe acute respiratory syndrome related coronavirus (SARSr-CoV), and for diagnosis of SARSr-CoV infection.

A field effect transistor (FET) biosensor for virus detection of a selected virus within a sample volume is disclosed. The FET comprises a semiconductor substrate, a source and drain electrode on the substrate, the electrodes spaced to form a channel. A gate electrode carried on the substrate and located in the channel between the source and drain electrodes. An insulating layer is coupled to a top surface of the gate electrode and a bottom surface of the source and drain electrodes, with an open channel above the insulating layer. A channel material is coupled to the insulating layer. Aptamers are oriented within the open channel to bind to the channel material and with the selected virus to enable a detection of the selected virus by the FET biosensor based on a change in drain-source current at a selected gate voltage.

A method of sampling and testing for SARS-COV-2 virus in nasal and nasopharyngeal fluid using a plurality of microfluidic channels with a plurality of integrated electrodes in the microfluidic channels to detect the virus. In one example embodiment, a plurality of antibodies are fixed on a surface of at least one electrode by positive dielectrophoresis that increases the sensitivity of detection. Viral antigens bind to the antibodies separating from the fluid thereby signally that the virus is present as evidenced by the detection of the antigens. Sampling by microfluidic channels is more comfortable to a patient because microfluidic channels are soft, flexible and narrow compared to swabs. Another example embodiment of a method using microfluidic channels for collecting tears or saliva to determine blood glucose levels using a smartphone that has been modified to incorporate external filters quantitate glucose levels is also described.

A method and process to make and use cotton-tipped electrochemical immunosensor for the detection of corona viruses is described. The immunosensor were fabricated by immobilizing the virus antigens on carbon nanofiber-modified screen printed electrodes which were functionalized by diazonium electrografting and activated by EDC/NHS chemistry. The detection of virus antigens were achieved via swabbing followed by competitive assay using fixed amount of antibody in the solution. Ferro/ferricyanide redox probe was used for the detection using square wave voltammetric technique. The limits of detection for our electrochemical biosensors were 0.8 and 0.09 pg/ml for SARS-CoV-2 and MERS-CoV, respectively indicating very good sensitivity for the sensors. Both biosensors did not show significant cross reactivity with other virus antigens such as influenza A and HCoV, indicating the high selectivity of the method.